<DOC>
	<DOC>NCT00783484</DOC>
	<brief_summary>First in human study to evaluate the safety, tolerability, and pharmacokinetics of PF-03716539. The potential of PF-03716539 to increase the concentrations of midazolam, darunavir and maraviroc will also be evaluated.</brief_summary>
	<brief_title>A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Body Mass Index (BMI) of approximately 18 to 30 kg/m2. Total body weight &gt;50 kg (110 lbs). Pregnant or nursing females. females of childbearing potential. Evidence or history of clinically significant hematological, renal (including kidney stones), endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or clinical findings at screening. Treatment with an investigational drug within 30 days (or determined by the local requirement, whichever is longer) or 5 halflives preceding the first dose of study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>First in Human (FIH), PF-03716539, PK enhancer</keyword>
</DOC>